You just read:

Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension

News provided by

Theravance Biopharma, Inc.

Jan 28, 2019, 08:30 ET